Full-Time

Chief of Staff

President and Chief Operating Officer

Posted on 8/27/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$160k - $265kAnnually

+ Performance Bonus + Equity

Senior, Expert

San Francisco, CA, USA

Hybrid position based in San Francisco, CA.

Category
Computational Biology
Genomics
Biology & Biotech
Requirements
  • Passion for delivering life-changing treatment options into the hands of patients
  • Familiarity with the drug discovery & development process
  • Strong communication skills, and an analytical mindset
  • Demonstrated ability to solve problems using a structured, analytical approach
  • Ability to handle multiple projects simultaneously
  • Comfort working independently and as part of a diverse team
  • Exceptional written communication and presentation skills
  • Comfort with ambiguity and a self-starter attitude
  • Extremely fast learner
  • Exquisitely detail-oriented
  • 2-3 years of experience in a top-tier professional services firm (e.g., consulting or banking)
  • Some experience in an operational role in biotech a plus
  • Ph.D., MD, or other graduate degrees in the life sciences a plus
Responsibilities
  • Ensure cross-functional alignment and harmonization of strategy with operational activities for BridgeBio Services departments
  • Collaborate with functional experts as a strategic partner to support the work of BridgeBio Services departments
  • Discuss findings of relevant strategic analyses with senior leadership
  • Ideate and manage strategic initiatives, organize, and interpret incoming data
  • Evaluate, articulate, and define strategy for ongoing BridgeBio Services initiatives
  • Help define / lead strategic initiatives
  • Manage key meetings with Senior leaders across BridgeBio Services
  • Perform other strategic analyses and projects as needed

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

3%

1 year growth

2%

2 year growth

-2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

INACTIVE